| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Mauro Panteghini | Q56418921 |
| Roberto Dominici | Q59286304 | ||
| P2093 | author name string | Daniela Cardinale | |
| Maria T Sandri | |||
| Alberto Dolci | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 688-695 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | American Journal of Clinical Pathology | Q15750224 |
| P1476 | title | Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use | |
| P478 | volume | 130 |
| Q50085564 | A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction. |
| Q38975452 | An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures |
| Q64278701 | Anthracycline induced cardiotoxicity in adult cancer patients: a prospective cohort study from a specialized oncology treatment centre in Uganda |
| Q34626238 | Anthracycline-associated cardiotoxicity in survivors of childhood cancer |
| Q33896047 | Assessment of cardiotoxicity with cardiac biomarkers in cancer patients |
| Q28538548 | BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography |
| Q57163637 | Bioinformatics identification of potential candidate blood indicators for doxorubicin-induced heart failure |
| Q38015746 | Biological drugs: classic adverse effects and new clinical evidences |
| Q49315568 | Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights |
| Q58904988 | Bringing new players into the field: onco-pharmacovigilance in the era of cardio-oncology |
| Q35216420 | Cancer chemotherapy induces cardiotoxicity by targeting cardiac stem cells |
| Q38735433 | Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions |
| Q92408562 | Cardiac Troponins are Among Targets of Doxorubicin-Induced Cardiotoxicity in hiPCS-CMs |
| Q51739297 | Cardiac complications of chemotherapy: role of biomarkers. |
| Q36117002 | Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity? |
| Q33574045 | Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention |
| Q41704131 | Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment |
| Q38021523 | Cardiotoxicity of childhood cancer treatment: update and current knowledge on long-term follow-up |
| Q54959206 | Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. |
| Q51224671 | Chemotherapy-induced Cardiotoxicity. |
| Q39415815 | Chemotherapy-induced cardiotoxicity in children |
| Q92218673 | Chemotherapy-related Cardiomyopathy |
| Q52553038 | Cisplatin and cisplatin analogues perfusion through isolated rat heart: the effects of acute application on oxidative stress biomarkers. |
| Q36006389 | Clinical cardiac safety profile of nilotinib |
| Q61448003 | Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q90343457 | Cytotoxic-induced heart failure among breast cancer patients in Nigeria: A call to prevent today's cancer patients from being tomorrow's cardiac patients |
| Q57794178 | Developing a panel of biomarkers and miRNA in patients with myocardial infarction for early intervention strategies of heart failure in West Virginian population |
| Q44849977 | Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. |
| Q28271060 | Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications |
| Q39774754 | Effects of thymoquinone against cisplatin-induced cardiac injury in rats. |
| Q36678516 | Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation |
| Q26785410 | Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors |
| Q38559133 | Heart failure and chemotherapeutic agents |
| Q26740352 | Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference? |
| Q50948084 | Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats. |
| Q48316178 | Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. |
| Q37434061 | Perspective on the clinical application of troponin in heart failure and states of cardiac injury |
| Q35039202 | Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury |
| Q34520935 | Present state and future perspectives of using pluripotent stem cells in toxicology research |
| Q58768520 | Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer |
| Q38237495 | Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway |
| Q35797623 | Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group |
| Q36416745 | Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines |
| Q27007849 | Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients |
| Q38173227 | Stem cells and stem cell-derived tissues and their use in safety assessment. |
| Q26743433 | The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy |
| Q27686758 | The cell biology of disease: cellular mechanisms of cardiomyopathy. |
| Q47375125 | The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT. |
| Q38140759 | The evolving role of cardiac troponin in the evaluation of cardiac disorders |
| Q52777491 | The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults. |
| Q52982588 | The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. |
| Q38600479 | The use of circulating biomarkers in early clinical trials in patients with cancer |
| Q35043809 | The utility of cardiac stress testing for detection of cardiovascular disease in breast cancer survivors: a systematic review |
| Q37926954 | Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist. |
| Q38097736 | Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively |
| Q33404672 | Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model |
| Q36527607 | Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality |
| Q27027354 | Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity |
| Q38069202 | Using cardiac biomarkers and treating cardiotoxicity in cancer |
Search more.